＞98%

Store at -20℃ for one year（Powder）；Store at 2-4℃ for two weeks；Store at -20℃ for six months after dissolution.

西曲溴铵；十六烷基三甲基溴hua铵；Cetyltrimethylammonium Bromide； Hexadecyltrimethylammonium bromide； CTAB

白色粉末

DMSO : 5 mg/mL (13.71 mM)

Ethanol : 93 mg/mL (255.2 mM)

Water : 92 mg/mL (252.4 mM)

Cetrimonium Bromide reduces cell viability of FaDu, C666-1, UTSCC-8A, UTSCC-42A, MRC5 cells and GM05757 fibroblasts with EC50 of 2 μM, 3.8 μM, 3.5 μM, 4.2 μM, 11 μM and 18 μM, respectively. Cetrimonium Bromide reduces cell viability of A549 lung and MCF7 breast cancer cells with EC50 of 17 μM and 12 μM. Cetrimonium Bromide (0.5 μM) interacts additively with radiation in a dose-dependent manner to exhibits inhibition effect on the clonogenic survival of FaDu cells. Cetrimonium Bromide results in nuclear condensation and blebbing in FaDu cells, consistent with apoptotic nuclear morphology, which is not observed in CTAB-treated GM05757 fibroblasts. Cetrimonium Bromide reproducibly decreases ATPase activity in a dose-dependent manner in FaDu cells, achieving ∼90% inhibition at 50 μM. Cetrimonium Bromide (5 μM) causes a modest (∼10%), but statistically significant decreases in ATP content in FaDu cells. Cetrimonium Bromide (5 μM) induced apoptosis is significantly suppressed by >50% when CCCP (5 μM) is used to effectively uncouple ΔΨM before Cetrimonium Bromide treatment in FaDu cells.

Cetrimonium Bromide (5 μM) effectively eliminates the tumor-forming potential of FaDu cells in SCID mice. Cetrimonium Bromide (daily 5 mg/kg i.p. for 5 days) induces a modest reduction in tumor development compared with the vehicle-treatment arm in established FaDu xenograft tumors in SCID mice.